BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
Gastrointestinal RSS Feed RSS

Lab glassware and antibodies art concept
Inflammatory

Series A financing at Bambusa to advance bispecific antibodies for immunological and inflammatory disorders

Feb. 17, 2025
Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting bispecific antibodies for immunological and inflammatory disorders.
Read More
Illustration of intestinal track
Inflammatory

Adiponectin blocks immunotherapy inflammation without impairing it

Feb. 17, 2025
By Mar de Miguel
Stimulating the body’s immune defenses against a tumor can reduce or eliminate it. However, in cancer immunotherapy, when immune checkpoint inhibitors unleash the immune system, severe autoimmunity can result. A hematological technique, extracorporeal photopheresis (ECP), could offer a solution. It reduces the therapy-induced inflammation without altering antitumor immunity. According to scientists at the Universities of Basel and Freiburg, the key lies in adiponectin, a hormone produced by fatty tissue.
Read More
Wooden stamp with China flag

Microport’s laparoscopic surgical robot cleared in China

Feb. 14, 2025
By Marian (YoonJee) Chu
Shanghai Microport Medbot (Group) Co. Ltd. won China National Medical Products Administration approval of its self-developed Toumai single-arm and single-port laparoscopic surgical robot.
Read More
Colorectal cancer illustration
Cancer

HMGA1 modulates Wnt-driven tumorigenesis in colorectal cancer

Feb. 12, 2025
A recent study published in the Journal of Clinical Investigation by researchers at Johns Hopkins University School of Medicine and collaborators identified HMGA1 as a key epigenetic regulator that enhances Wnt signaling in colon cancer.
Read More
Illustration of insulin receptors not responding properly to insulin binding
Endocrine/metabolic

Adrenomedullin pathway leads to insulin resistance in obesity

Feb. 12, 2025
By Mar de Miguel
Adrenomedullin, a hormone first identified in an adrenal medullary tumor, disrupts the effect of insulin on the endothelium of blood vessels, leading to insulin resistance linked to obesity and type 2 diabetes. The clue to this discovery lies in a molecular pathway that could be blocked to restore insulin function.
Read More
Gastrointestinal system with ulcerative colitis.
Gastrointestinal

PALI-2108 colon-activated prodrug prevents ulcerative colitis progression

Feb. 11, 2025
Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include 5-aminosalicylates, corticosteroids or anti-TNF agents, but there is a need for new strategies to obtain higher remission rates and less systemic immunosuppression.
Read More
Art concept for inflammation in the intestines
Gastrointestinal

Anti-DR3 antibody demonstrates efficacy in the treatment of IBD

Feb. 11, 2025
Death receptor 3 (DR3) is the only signaling receptor for TNF superfamily ligand TL1A, the dysregulation of which has been implicated in multiple inflammatory diseases such as inflammatory bowel disease (IBD). Blockade of TL1A has been shown to induce significant clinical responses in IBD.
Read More
Pancreas
Gastrointestinal

Study HINTs at new target for acute pancreatitis

Feb. 5, 2025
Acute pancreatitis (AP) is a gastrointestinal disorder characterized by inflammation and necrosis of the pancreatic acinar cells. Mitochondrial homeostasis is key to energy metabolism and redox homeostasis, both of which are essential for pancreatic functioning, where oxidative phosphorylation (OXPHOS) plays a crucial role.
Read More

More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal

Feb. 4, 2025
By Marian (YoonJee) Chu
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
Read More
Gastrointestinal

MR-2938 regulates gut microbiota composition and alleviates DSS-induced colitis

Feb. 3, 2025
Researchers from Ocean University of China and Qingdao Marine Science and Technology Center published data from a preclinical study that investigated the impact of the quinazolinone derivative MR-2938 on gut microbiota during colitis. A dextran sodium sulfate (DSS)-induced colitis mouse model was constructed, and the animals were treated with MR-2938 (50 or 100 mg/kg).
Read More
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 713 714 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing